Eizo Kimura

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi et al. · The Lancet · 2009 · 733 citations

Medicine, Oncology, Pharmacology +12

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi et al. · The Lancet Oncology · 2013 · 481 citations

Medicine, Gynecology, Oncology +13

Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60.

Eizo Kimura, Robert E. Enns, Jordi Alcaraz et al. · Journal of Clinical Oncology · 1993 · 72 citations

Medicine, Molecular Biology, Oncology +16

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women

Hiroyuki Fujiwara, Mitsuaki Suzuki, Nobuhiro Takeshima et al. · Tumor Biology · 2014 · 52 citations · Full text

Medicine, Gynecology, Oncology +17

Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology

Seiji Isonishi, Makoto Yasuda, Fumiaki Takahashi et al. · Journal of Clinical Oncology · 2008 · 37 citations

Medicine, Oncology, Pharmacotherapy +14